Original multivalent copper(II)-conjugated phosphorus dendrimers and corresponding mononuclear copper(II) complexes with antitumoral activities

Molecular Pharmaceutics

Volumn 10, Issue 4, 2013, Pages 1459-1464

  El Brahmi, Nabil ^a,c,e   El Kazzouli, Saïd ^a   Mignani, Serge M ^b   Essassi, El Mokhtar ^c   Aubert, Genevieìve ^d   Laurent, Régis ^e   Caminade, Anne Marie ^e   Bousmina, Mosto M ^f,g   Cresteil, Thierry ^d   Majoral, Jean Pierre ^e  

^a Institute of Nanomaterials and Nanotechnology (INANOTECH)   (Morocco)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c FACULTÉ DES SCIENCES   (Morocco)

^d INSTITUT DE CHIMIE DES SUBSTANCES NATURELLES   (France)

^e LCC LABORATOIRE DE CHIMIE DE COORDINATION   (France)

^f HASSAN II ACADEMY OF SCIENCE AND TECHNOLOGY   (Morocco)

^g Euro Mediterranean University of Fes (UEMF)   (Morocco)

Author keywords

antiproliferative properties; copper complexes; dendrimers; nanomedicine; phosphorus

Indexed keywords

ANTINEOPLASTIC AGENT; COPPER DERIVATIVE; DENDRIMER; N (PYRIDIN 2 YLMETHYLENE)ETHANAMINE; PHOSPHORUS DERIVATIVE; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONJUGATE; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; IC 50; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOCOMPATIBLE MATERIALS; CARPS; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; COPPER; DENDRIMERS; DRUG DESIGN; HL-60 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, CHEMICAL; MOLECULAR STRUCTURE; NANOMEDICINE; PHOSPHORUS;

EID: 84875764628     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp4000184     Document Type: Article

References (45)

1. Available at http://www.who.int/mediacentre/factsheets/fs297/en/ (accessed January 2013).
2. Jemal, A.; Bray, F.; Center, M. M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics Cancer J. Clin. 2011, 61, 69-90
3. Ferrari, M. Cancer nanotechnology: opportunities and challenges Nat. Rev. Cancer 2005, 5, 161-171
4. Peer, D.; Karp, J. M.; Hong, S.; Farokhzad, O. C.; Margalit, R.; Langer, R. Nanocarriers as an emerging platform for cancer therapy Nat. Nanotechnol. 2007, 2, 751-760
5. Amiji, M. M. Nanotechnology-Improving Targeted Delivery Nanotechnology 2007, 53
6. Parveen, S.; Misra, M. S. R.; Sahoo, S. K. Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging Nanomed. Nanotechnol., Biol. Med. 2011, 8, 147-166
7. Kievit, F. M.; Zhang, M. Surface engineering of iron oxide nanoparticles for targeted cancer therapy Acc. Chem. Res. 2011, 44, 853-862 and references cited therein
8. van Zutphen, S.; Reedijk, J. Targeting platinum anti-tumour drugs: Overview of strategies employed to reduce systemic toxicity Coord. Chem. Rev. 2005, 24, 2845-2853
9. Gabano, E.; Ravera, M.; Colangelo, D.; Osella, D. Bioinorganic Chemistry: The study of metallodrug fate of platinum-based antitumour drugs Curr. Chem. Biol. 2007, 1, 278-289
10. Gabano, E.; Ravera, M.; Osella, D. The drug targeting and delivery approach applied to Pt-antitumour complexes. A coordination point of view Curr. Med. Chem. 2009, 16, 4544-4580
11. Harper, B. W.; Krause-Heuer, A. M.; Grant, M. P.; Manohar, M.; Garbutcheon-Singh, K. B.; Aldrich-Wright, J. R. Advances in Platinum Chemotherapeutics Chem.-Eur. J. 2010, 16, 7064-7077 and references cited therein
12. 6-hexamethylbenzene) ruthenium(II) chloroform monosolvate J. Organomet. Chem. 2009, 694, 3470-3476
13. Chavain, N.; Biot, C. Organometallic complexes: new tools for chemotherapy Curr. Med. Chem. 2010, 17, 2729-2745
14. Ruiz-Azuara, L.; Bravo-Gomez, M. E. Copper compounds in cancer chemotherapy Curr. Med. Chem. 2010, 17, 3606-1615
15. Rodrigues, J.; Jardin, M. G.; Figueira, J.; Gouveia, M.; Tomas, H.; Rissanen, K. Poly(alkylidenamines) dendrimers as scaffolds for the preparation of low-generation ruthenium based metallodendrimers New J. Chem. 2011, 35, 1938-1943
16. Gasser, G.; Oh, I.; Metzler-Nolte, N. Organometallic Anticancer compounds J. Med. Chem. 2011, 54, 3-25
17. El Kazzouli, S.; El Brahmi, N.; Mignani, S.; Bousmina, M.; Zablocka, M.; Majoral, J.-P. From metallodrugs to metallodendrimers for nanotherapy in oncology: a concise overview Curr. Med. Chem. 2012, 19, 4995-5010
18. Govender, P.; Therrien, B.; Smith, G. S. Bio-Metallodendrimers-Emerging Strategies in Metal-Based Drug Design Eur. J. Inorg. Chem. 2012, 2853-2862 and references cited therein
19. Gillies, E. R.; Fréchet, J. M. Dendrimers and Dendritic Polymers in Drug Delivery Drug Discovery Today 2005, 10, 35-43
20. Caminade, A.-M.; Majoral, J. P. Water-soluble phosphorus-containing dendrimers Prog. Polym. Sci. 2005, 30, 491-505
21. McCarthy, T. D.; Karellas, P.; Henderson, S. A.; Giannis, M.; O'Keefe, D. F.; Heery, G.; Paull, J. R. A.; Matthews, B. R.; Holan, G. Dendrimers as drugs: Discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention Mol. Pharmaceutics 2005, 2, 312-318
22. Griffe, L.; Poupot, M.; Marchand, P.; Maraval, A.; Turrin, C. O.; Rolland, O.; Metivier, P.; Bacquet, G.; Fournie, J. J.; Caminade, A.-M.; Poupot, R.; Majoral, J.-P. Tailored control and optimization of the number of phosphonic acid termini on phosphorus-containing dendrimers for the ex-vivo activation of human monocytes Chem.-Eur. J. 2008, 14, 4836-4850
23. Wolinsky, J. B.; Mark, W.; Grinstaff, M. Advanced Therapeutic and diagnostic applications of dendrimers for cancer treatment Drug Delivery Rev. 2008, 60, 1037-1055
24. Mintzer, M. A.; Grinstaff, M. W. Biomedical applications of dendrimers: a tutorial Chem. Soc. Rev. 2010, 40, 173
25. Astruc, D.; Boisselier, E.; Omelas, C. Dendrimer designed for functions: from physical, and supramolecular properties to applications in sensing, catalysis, molecular electronic, photonics, and nanomedicine Chem. Rev. 2010, 110, 1857-1959
26. Menjoge, A. R.; Kannan, R. M.; Tomalia, D. A. Dendrimer-Based Drug and Imaging Conjugates: Design Considerations for Nanomedical Applications Drug Discovery Today 2010, 15, 171-185
27. Maksimenko, A. V.; Mandrouguine, V.; Gottikh, M. B.; Bertrand, J. R.; Majoral, J.-P.; Malvy, C. Optimisation of dendrimer-mediated gene transfer by anionic oligomers J. Gene Med. 2003, 5, 61-71
28. Spataro, G.; Malecaze, F.; Turrin, C. O.; Soler, V.; Duhayon, C.; Elena, P. P.; Majoral, J.-P.; Caminade, A.-M. Designing dendrimers for ocular drug delivery Eur. J. Med. Chem. 2010, 45, 326-334
29. El Kazzouli, S.; Mignani, S.; Bousmina, M.; Majoral, J.-P. Dendrimer therapeutics: covalent and ionic attachments New J. Chem. 2012, 36, 227-240
30. Khandare, J.; Calderon, M.; Dagia, N. M.; Haag, R. Multifunctional dendritic polymers in nanomedicine: opportunities and challenges Chem. Soc. Rev. 2012, 41, 2824-2848
31. Available at http://www.starpharma.com/vivagel (accessed in January 2013).
32. Gajbhiye, V.; Palanirajan, V. K.; Tekade, R. K.; Jain, N. K. Dendrimers as therapeutic agents: a systematic review J. Pharm. Pharmacol. 2009, 61, 989-1003
33. Caminade, A.-M.; Turrin, C.-O.; Majoral, J.-P. Biological properties of phosphorus dendrimers New. J. Chem. 2010, 34, 1512-1524
34. Hayder, M.; Poupot, M.; Baron, M.; Nigon, D.; Turrin, C. O.; Caminade, A. M.; Majoral, J.-P.; Eisenberg, R. A.; Fournie, J. J.; Cantagrel, A.; Poupot, R.; Davignon, J. L. A phosphorus-based dendrimer targets inflammation and osteoclastogenesis in experimental arthritis Sci. Transl. Med. 2011, 3, 81ra35
35. Launay, N.; Caminade, A.-M.; Lahana, R.; Majoral, J.-P A general synthetic strategy for neutral phosphorus-containing dendrimers Angew. Chem., Int. Ed. Engl. 1994, 33, 1589-1592
36. Galliot, C.; Larré, C.; Caminade, A.-M.; Majoral, J.-P. Regioselective stepwise growth of dendrimer units in the internal voids of a main dendrimer Science 1997, 277, 1981-1984
37. Merino, S.; Brauge, L.; Caminade, A.-M.; Majoral, J.-P.; Taton, D.; Gnanou, Y. Synthesis and characterization of linear, hyperbranched, and dendrimer-like polymers constituted of the same repeating unit Chem.-Eur. J. 2001, 7, 3095-3105
38. Cavero, E.; Zablocka, M.; Caminade, A. M.; Majoral, J.-P. Design of bisphosphonate-terminated dendrimers Eur. J. Org. Chem. 2010, 14, 2759-2767
39. Ciepluch, K.; Katir, N.; El Kadib, A.; Felczak, A.; Zawadzka, K.; Weber, M.; Klajnert, B.; Lisowska, K.; Caminade, A.-M.; Bousmina, M.; Bryszewska, M.; Majoral, J.-P. Biological properties of new viologen-phosphorus dendrimers Mol. Pharmaceutics 2012, 9, 448-457
40. Wang, T.; Guo, Z. Copper in medicine: homeostasis, chelation therapy and antitumor drug design Curr. Med. Chem. 2006, 13, 525-537
41. Marzano, C.; Pellei, M.; Tisato, F.; Santini, C. Copper complexes as anticancer agents Anticancer Agents Med. Chem. 2009, 9, 185-211
42. Ruiz-Azuara, L.; Bravo-Gomez, M. E. Copper compounds in cancer chemotherapy Curr. Med. Chem. 2010, 17, 3606-3615
43. Rodrigues, J.; Jardim, M. G.; Figueira, J.; Gouveia, M.; Tomas, H.; Rissanen, K. Poly(alkylidenamines) dendrimers as scaffolds for the preparation of low-generation ruthenium based metallodendrimers New J. Chem. 2011, 35, 1938-1943 and references cited therein
44. Zhao, X.; Loo, S. C. J.; Lee, P. P.; Tan, T. T. Y.; Chu, C. K. Synthesis and cytotoxic activities of chloropyridylimineplatinum(II) and chloropyridyliminecopper(II) surface-functionalized poly(amidoamine) dendrimers J. Inorg. Biochem. 2010, 104, 105-110
45. Govender, P.; Renfrew, A. K.; Chavel, C. M.; Dyson, P. J.; Therrien, B.; Smith, G. S. Antiproliferative activity of chelating N,O- and N,N -ruthenium(II) arene functionalised poly(propyleneimine) dendrimer scaffolds Dalton Trans. 2011, 40, 1158-1167